SGO Annual Meeting on Women's Cancer
Highlights from the 48th Annual Meeting of the Society of Gynecologic Oncology, featuring the latest research and insights from those who treat and care for women with gynecologic cancer.
Rucaparib Shows Promising Activity in Recurrent Ovarian Cancer
BY BRIELLE URCIUOLI
Elizabeth Swisher, M.D., discusses the ARIEL2 study, which proved that rucaparib may be a promising agent for patients with recurrent ovarian cancer.
Elizabeth Swisher Discusses Rucaparib's Side Effects for Patients With Ovarian Cancer
BY ELIZABETH SWISHER, M.D.
Elizabeth Swisher, M.D., professor, Department of Medicine, Division of Medical Genetics, University of Washington School of Medicine, Breast and Ovarian Cancer Prevention Program, Seattle Cancer Care Alliance, discusses the side effects of rucaparib in the ARIEL2 trial, for patients with relapsed, platinum-sensitive high-grade ovarian carcinoma.
Special Feature
Share Your Art
ONS Awards 2017
 
Cure Connections
x